Gujarat Kidney and Super Speciality IPO: Complete Guide to Subscription, Listing & Fund Utilisation
The Gujarat Kidney and Super Speciality IPO, a fresh equity issue worth ₹250.80 crore, grabbed notable attention in December 2025 due to strong subscription numbers and promising growth plans. This blog covers everything investors need to know — from subscription details and listing dates to how the funds will be utilised and what makes this IPO a hot opportunity in India’s booming healthcare sector.
Gujarat Kidney and Super Speciality IPO Overview
The Gujarat-based healthcare provider launched its IPO on December 22, 2025, and it closed on December 24, 2025. This 100% fresh issue comprised 2.20 crore shares priced between ₹108 and ₹114 per share, with a minimum lot size of 128 shares. The issue raised ₹250.80 crore aimed at expansion and acquisitions.
- IPO Size: ₹250.80 crore (fresh issue)
- Price Band: ₹108–₹114 per share
- Lot Size: 128 shares (≈₹14,592 minimum retail investment)
- Issue Type: Book-built 100% fresh issue
- Lead Manager: Nirbhay Capital Services
- Registrar: MUFG Intime India
Subscription Performance and Listing Details
The IPO witnessed robust investor interest, closing with an overall subscription level of 5.21 times. The retail investor segment was particularly enthusiastic, with a subscription nearly 13 times, signaling strong confidence from individual investors. Non-Institutional Investors (NIIs) showed a strong but moderate response, while Qualified Institutional Buyers (QIBs) were comparatively moderate.
Here is the IPO timeline investors should note:
- Opening Date: December 22, 2025
- Closing Date: December 24, 2025 (UPI payment deadline 5 PM)
- Allotment Date: December 26, 2025
- Refunds & Share Credit: December 29, 2025
- Listing Date: December 30, 2025 on NSE and BSE
Company Profile & Operations
Gujarat Kidney and Super Speciality Ltd operates seven multi-speciality hospitals and four in-house pharmacies across prominent Gujarat cities: Vadodara, Godhra, Bharuch, Borsad, and Anand. Their healthcare infrastructure includes 490 beds in total—445 approved and 340 operational beds.
The company’s core services entail:
- Secondary and tertiary care
- Inpatient and outpatient services
- Diagnostics and surgery
- Critical care and pharmacy services
The focus is to provide super-speciality healthcare, with emphasis on nephrology and urology under the leadership of Dr. Pragnesh Yashwantsinh Bharpoda, the company’s promoter, Chairman, and Managing Director since January 2025. He holds advanced medical degrees (MBBS, MS, MCh Urology) and drives the group’s expansion.
Fund Utilisation: Strategic Expansion and Modernisation
The ₹250 crore raised will be channelled into several key projects and acquisitions to widen the company’s footprint in Gujarat’s healthcare landscape.
| Purpose | Amount (₹ Crore) | Description |
|---|---|---|
| Acquisition of Parekhs Hospital (Ahmedabad) | 77.00 | Bolsters presence in Ahmedabad, Gujarat’s major city |
| Part-Payment for Ashwini Medical Centre | 12.40 | Continued expansion via hospital acquisition |
| New Women-Exclusive Hospital (Vadodara) | 30.10 | Addresses growing demand for specialised women’s healthcare |
| Stake Acquisition in Harmony Medicare (Bharuch) | 10.78 | Increasing regional market share |
| Robotics Equipment | 6.83 | Modernising surgical facilities with robotics |
| Debt Repayment | 1.20 | Reducing financial liabilities |
| General Corporate Purposes | 112.49 | Working capital and other expenses |
Why is Gujarat Kidney IPO Trending?
There are several reasons why this IPO caught the market’s attention:
- Explosive Subscription Surge: The massive jump on Day 3 indicated strong retail demand.
- Positive Grey Market Premium (GMP): Suggests good listing prospects with potential gains for early investors.
- Healthcare Sector Growth: India’s healthcare segment is expanding fast, driven by rising urbanisation and demand for specialised care.
- Regional Market Leadership: The company’s existing strong presence in underserved Gujarat markets provides scalability.
- Focus on Technology & Women’s Healthcare: Investments in robotics and women-exclusive hospitals meet modern healthcare needs.
Key Questions Investors Ask (People Also Ask)
What is the Gujarat Kidney IPO subscription status on Day 3?
The IPO closed with a strong overall subscription of 5.21x, with retail investors showing nearly 13x subscription, highlighting keen interest among individual investors.
When is Gujarat Kidney IPO listing date?
The company is set to list on the NSE and BSE on December 30, 2025, following allotment on December 26 and share credits by December 29.
How will Gujarat Kidney hospital IPO funds be used?
The funds will be mainly used for acquiring hospitals like Parekhs Hospital in Ahmedabad, establishing a women-exclusive hospital in Vadodara, acquiring stake in Harmony Medicare, upgrading with robotics equipment, partial debt repayment, and general corporate purposes.
Who is the promoter of Gujarat Kidney and Super Speciality?
Dr. Pragnesh Yashwantsinh Bharpoda is the promoter, Chairman, and MD, a highly qualified urology and nephrology expert, leading company growth since 2023 as Director and since 2025 as MD.
Actionable Takeaways for Investors
- If you’re a retail investor looking for exposure to India’s fast-growing healthcare sector, Gujarat Kidney IPO’s robust retail subscription indicates positive market sentiment and potential listing gains.
- Understand the company’s expansion strategy focusing on acquisitions and modern facilities such as robotic surgery, which can drive future profitability.
- Check your application status post allotment date (Dec 26, 2025) and expect shares in your demat account by December 29, before NSE/BSE listing.
- Monitor grey market premium (GMP) trends pre-listing for better exit timing strategies.
FAQs
What sectors does Gujarat Kidney and Super Speciality operate in?
They operate primarily in secondary and tertiary healthcare, offering inpatient and outpatient services, diagnostics, surgeries, critical care, and pharmacy operations.
Is the IPO primarily a fresh issue or an offer for sale?
This IPO is a 100% fresh issue to raise ₹250.80 crore for expansion, with no shares offered for sale by existing investors.
Who managed the Gujarat Kidney IPO?
Nirbhay Capital Services served as the lead manager, and MUFG Intime India was the registrar.
What is the minimum investment amount for retail investors?
The lot size is 128 shares, approximately ₹14,592 at the upper price band of ₹114 per share.
Where can I check Gujarat Kidney IPO detailed subscription status?
You can visit trusted financial portals such as VaultStreet or Zerodha IPO for updated subscription and GMP trends.
Conclusion
Gujarat Kidney and Super Speciality’s IPO marks a significant milestone for regional healthcare expansions in Gujarat, combining strong financial backing with strategic acquisitions and technology investments. With retail enthusiasm at nearly 13x subscription and a promising business model focused on underserved markets, this IPO presents an excellent opportunity for investors seeking growth in India’s resilient healthcare sector.
Watch the allotment and listing dates closely and use credible financial platforms for the latest updates to make informed investment decisions.
0 Comments